4D Molecular Therapeutics (4DMT) will showcase its clinical development programs across three prominent investor conferences scheduled throughout March 2026. The company's management team is set to present at the TD Cowen Health Care Conference on March 3, the Leerink Global Healthcare Conference on March 10, and the Barclays Global Healthcare Conference on March 12. These presentations will provide institutional investors with updates on the company's late-stage therapeutic candidates.
Among the key programs expected to be discussed is 4D-150, a treatment for retinal vascular diseases currently advancing through Phase 3 clinical trials. Additionally, 4DMT will likely highlight progress on 4D-710, its therapeutic candidate targeting cystic fibrosis. The conference schedule reflects a concentrated investor outreach effort during the first quarter of 2026, a typical period for biotech companies to engage the financial community on clinical advancement and pipeline developments.
The three conferences represent major forums where emerging and established healthcare companies present their strategic direction and clinical achievements to sell-side analysts, institutional investors, and fund managers who closely monitor the therapeutic development landscape.